The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: study protocol for a randomised controlled trial
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Antidepressant medication is commonly used to treat depression. However, many patients do not respond to the first medication prescribed and improvements in symptoms are generally only detectable by clinicians 4-6 weeks after the medication has been initiated. As a result, there is often a long delay between the decision to initiate an antidepressant medication and the identification of an effective treatment regimen. Previous work has demonstrated that antidepressant medications alter subtle measures of affective cognition in depressed patients, such as the appraisal of facial expression. Furthermore, these cognitive effects of antidepressants are apparent early in the course of treatment and can also predict later clinical response. This trial will assess whether an electronic test of affective cognition and symptoms (the Predicting Response to Depression Treatment Test; PReDicT Test) can be used to guide antidepressant treatment in depressed patients and, therefore, hasten treatment response compared to a control group of patients treated as usual. METHODS/DESIGN: The study is a randomised, two-arm, multi-centre, open-label, clinical investigation of a medical device, the PReDicT Test. It will be conducted in five European countries (UK, France, Spain, Germany and the Netherlands) in depressed patients who are commencing antidepressant medication. Patients will be randomised to treatment guided by the PReDicT Test (PReDicT arm) or to Treatment as Usual (TaU arm). Patients in the TaU arm will be treated as per current standard guidelines in their particular country. Patients in the PReDicT arm will complete the PReDicT Test after 1 (and if necessary, 2) weeks of treatment. If the test indicates non-response to the treatment, physicians will be advised to immediately alter the patient's antidepressant therapy by dose escalation or switching to another compound. The primary outcome of the study is the proportion of patients showing a clinical response (defined as 50% or greater decrease in baseline scores of depression measured using the Quick Inventory of Depressive Symptoms - Self-Rated questionnaire) at week 8. Health economic and acceptability data will also be collected and analysed. DISCUSSION: This trial will test the clinical efficacy, cost-effectiveness and acceptability of using the novel PReDicT Test to guide antidepressant treatment selection in depressed patients. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT02790970 . Registered on 30 March 2016.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The size and burden of mental disorders and other disorders of the brain in Europe 2010
Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jönsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.018 · Cited by 3,754
Ferrari, A. J., Charlson, F. J., Norman, R. E., Patten, S. B., Freedman, G., Murray, C. J. L., Vos, T., & Whiteford, H. A. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001547 · Cited by 3,115
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435 · cited 1×
“While there is no general agreement on minimum clinically relevant effect size, a review of the US Food and Drug Administration (FDA) data on antidepressant randomised controlled trials (RCTs) found that in RCTs of antidepressants versus placebo a minimum of 11% difference in response was significant and measurable [1…”
BackgroundAnalysing controlled trials with baseline and follow up measurements
Vickers, A. J., & Altman, D. G. (2001) · BMJ · doi:10.1136/bmj.323.7321.1123 · Cited by 2,116
Scaling-up treatment of depression and anxiety: a global return on investment analysis
Chisholm, D., Sweeny, K., Sheehan, P., Rasmussen, B., Smit, F., Cuijpers, P., & Saxena, S. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30024-4 · Cited by 1,451 · cited 1×
“It is associated with significant socioeconomic costs and has been predicted to become the greatest cause of disability worldwide by 2030 [2, 3].”
BackgroundJakobsen, J. C., Katakam, K. K., Schou, A., Hellmuth, S. G., Stallknecht, S. E., Leth-Møller, K., Iversen, M., Banke, M. B., Petersen, I. J., Klingenberg, S. L., et al. (2017) · BMC Psychiatry · doi:10.1186/s12888-016-1173-2 · Cited by 366 · cited 1×
“Conceivably, the ability to personalise treatment may also enhance the risk/benefit assessment of antidepressant use which has been questioned in a recent study which pooled data from clinical trials of the nonpersonalised use of antidepressants [25].”
BackgroundThe timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments
Machado-Vieira, R., Baumann, J., Wheeler-Castillo, C., Latov, D., Henter, I. D., Salvadore, G., & Zarate, C. A. (2010) · Pharmaceuticals · doi:10.3390/ph3010019 · Cited by 263 · cited 1×
“Clearly, the response of patients to antidepressant treatment is variable, with evidence from treatment trials indicating that separation from placebo can be detected at the group level after 1–2 weeks of treatment [26] and side effects commonly occurring early in the course of treatment.”
BackgroundHarmer, C. J., Hill, S. A., Taylor, M. J., Cowen, P. J., & Goodwin, G. M. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.5.990 · Cited by 262 · cited 6×
“(DOCX 49 kb) Abbreviations CE: Conformité Européene; DSST: Digit Symbol Substitution Test; ePRO: Electronic patient-reported outcomes; EQ-5D-5 L: 5-dimensional, 5-level EuroQoL health-related quality of life questionnaire; GAD-7: Generalised Anxiety Disorder Questionnaire, 7-item version; HEQ: Health Economics Questio…”
MethodInfluentialSelf-citationRuhé, H. G., Huyser, J., Swinkels, J. A., & Schene, A. H. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1203 · Cited by 230 · cited 1×
“Additionally, more than 50% of patients fail to respond to the first antidepressant treatment that they are prescribed [6, 7].”
BackgroundSelf-citationTranter, R., Bell, D., Gutting, P., Harmer, C., Healy, D., & Anderson, I. M. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.01.028 · Cited by 184 · cited 1×
“Consistent with this, the degree to which antidepressants induce these changes in emotional processing early in treatment is predictive of the later improvement in subjective symptoms as reported by depressed patients [9].”
BackgroundSelf-citation
Cited by
Rajula, H. S. R., Verlato, G., Manchia, M., Antonucci, N., & Fanos, V. (2020) · Medicina · doi:10.3390/medicina56090455 · Cited by 606
Treatment selection in depression.
Cohen, Z. D., & DeRubeis, R. J. (2018) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050817-084746 · Cited by 435
“To realize the promise of precision mental health, existing models as well as those that are being developed will need to be validated prospectively against standard allocation schemes (Kingslake et al. 2017).”
MethodBrowning, M., Kingslake, J., Dourish, C. T., Goodwin, G. M., Harmer, C. J., & Dawson, G. R. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.11.1102 · Cited by 83
Self-citationMenke, A. (2018) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s146110 · Cited by 41
“One example of a smartphone-based application is the Predicting Response to Depression Treatment Test (PReDicT Test).(142) Experimental evidence suggests that patients suffering from MDD are more likely to interpret facial expressions of emotion more negative than matched healthy controls.”
BackgroundMethodSelf-citation
Metadata
- Authors
- Kingslake, J., Dias, R., Dawson, G. R., Simon, J., Goodwin, G. M., Harmer, C. J., Morriss, R., Brown, S., Guo, B., Dourish, C. T., Ruhé, H. G., Lever, A. G., Veltman, D. J., van Schaik, A., Deckert, J., Reif, A., Stäblein, M., Menke, A., Gorwood, P., Voegeli, G., Pérez, V., & Browning, M.
- Venue
- Trials
- Published
- 2017-11-23
- Volume
- 18
- Issue
- 1
- Pages
- 558-558
- ISSN
- 1745-6215 (ISSN-L)
- OpenAlex
- W2770576596
- Cited by
- 42
- References
- 10
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.